Onkologie. 2011:5(4):200-202

Contemporary view on strategy of metastatic renal cell carcinoma therapy

Bohuslav Melichar, Hana Procházková-Študentová, Michaela Zezulová
Onkologická klinika LF UP a FN Olomouc

The last 10 years have witnessed a fundamental progress in the therapy of metastatic renal cell carcinoma. The development of targeted

therapy against vascular endotheial growth factor and mammalian target of rapamycin pathways has lead to the introduction of

a number of new agents, including sunitinib, sorafenib, bevacizumab, temsirolimus and everolimus into the treatment of this tumor.

Other drugs are in final phase of development and, currently, the research is focused on defining the optimal algorithm of targeted

therapy in this tumor.

Keywords: targeted therapy, renal cell carcinoma

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Melichar B, Procházková-Študentová H, Zezulová M. Contemporary view on strategy of metastatic renal cell carcinoma therapy. Onkologie. 2011;5(4):200-202.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-417. Go to original source... Go to PubMed...
    2. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin N Am 1993; 20: 303-321. Go to original source...
    3. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14-17. Go to original source...
    4. Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN-alfa and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85: 1130-1136. Go to original source... Go to PubMed...
    5. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994; 54: 4233-4237.
    6. Papac RJ, Poo-Hwu WJ. Renal cell carcinoma: A paradigm of lanthanic disease. Am J Clin Oncol 1999; 22: 223-231. Go to original source... Go to PubMed...
    7. Melichar B, Vaneckova J, Moravek P, Urminska H, Podhola M. Spontaneous regression of renal cell carcinoma lung metastases in a patient with psoriasis. Acta Oncol 2009; 48: 925-927. Go to original source... Go to PubMed...
    8. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1265-1271. Go to original source... Go to PubMed...
    9. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540. Go to original source... Go to PubMed...
    10. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-1659. Go to original source... Go to PubMed...
    11. Mickisch GHJ, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-970. Go to original source... Go to PubMed...
    12. Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995; 154: 32-34. Go to original source... Go to PubMed...
    13. Gatenby RA, Gawlinski ET, Tangen CM, Flanigan RC, Crawford ED. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res 2002; 62: 5218-5222.
    14. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 2261-2266. Go to original source... Go to PubMed...
    15. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg W, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 1928-1935. Go to original source... Go to PubMed...
    16. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-2867. Go to original source... Go to PubMed...
    17. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434. Go to original source... Go to PubMed...
    18. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524. Go to original source... Go to PubMed...
    19. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial gorwth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24. Go to original source... Go to PubMed...
    20. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134. Go to original source... Go to PubMed...
    21. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111. Go to original source... Go to PubMed...
    22. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428. Go to original source... Go to PubMed...
    23. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470-1476. Go to original source... Go to PubMed...
    24. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124. Go to original source... Go to PubMed...
    25. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-3748. Go to original source... Go to PubMed...
    26. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szcylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 61-67. Go to original source... Go to PubMed...
    27. Melichar B. How can second-line therapy for renal cell carcinoma help to define an overall management strategy? Oncology 2009; 77: 82-91. Go to original source... Go to PubMed...
    28. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patieints with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918. Go to original source... Go to PubMed...
    29. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. Go to original source... Go to PubMed...
    30. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.